What Alltrna does

Alltrna is a clinical-stage biotechnology company founded in 2018 by Flagship Pioneering and headquartered in Cambridge, Massachusetts. The company has built the world's first tRNA medicines platform, using proprietary machine learning tools to engineer chemically modified transfer RNA oligonucleotides designed to read through premature termination codons (PTCs) — nonsense mutations responsible for approximately 10% of all genetic disease, affecting an estimated 30 million patients worldwide. Alltrna's lead clinical candidate, AP003, is a liver-directed, lipid nanoparticle-encapsulated engineered tRNA targeting the Arg-TGA nonsense mutation, and was approved in March 2026 to enter a Phase 1 healthy-volunteer trial in Australia under the TGA Clinical Trial Notification scheme — the first engineered tRNA therapeutic to reach the clinic. Supporting pipeline programs target Gln-TAG liver indications and additional nonsense mutation types, with early-stage muscle and CNS programs extending the platform beyond the liver. The company has demonstrated preclinical proof-of-concept across 25 disease models, 14 genes, and 7 mutation locations, with ML-driven optimization yielding approximately 100-fold improvements in engineered tRNA activity.

The business model is entirely equity-financed and pre-revenue. Alltrna has raised $159 million cumulatively across its November 2021 launch ($50 million) and August 2023 Series B ($109 million), both led by Flagship Pioneering. Its intended go-to-market is a mutation-defined basket-trial strategy in which a single tRNA medicine can address thousands of distinct diseases sharing the same PTC, with eventual commercialization via biopharma out-licensing or co-development rather than direct sales. The company partners with Acuitas Therapeutics for clinically validated LNP delivery, with patient advocacy organizations NORD and NPKUA for community engagement, and operates a marketing approach built on scientific conferences, peer-reviewed publications, and earned media rather than paid acquisition.

As of early 2026, Alltrna faces notable operational headwinds alongside its clinical milestone: a third round of layoffs cut approximately 35% of its workforce (19 employees), and CEO Michelle C. Werner departed to join Ipsen as EVP and President of North America. Joanne Protano continues as President and CFO, and the AP003 Phase 1 trial proceeds under existing leadership, but the restructuring signals capital constraints that will likely necessitate a financing event or strategic transaction within the next 12-24 months to fund continued clinical development beyond the current Phase 1.

Name

Alltrna

Legal name

Alltrna

Website

https://alltrna.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

51–100 employees

Short description

Alltrna is a clinical-stage biotechnology company developing the world's first engineered tRNA medicines platform to restore protein production in thousands of genetic diseases caused by nonsense mutations. The Cambridge, MA-based Flagship Pioneering portfolio company is pre-revenue and recently initiated Phase 1 trials of lead candidate AP003.

Ownership category

akta.pro rank

Product category

tRNA Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

akta.pro secondary industries

RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry) (HLAAADAE), RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF), RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD)

Keywords

• TRNA therapeutics
• Engineered tRNA medicines
• Stop codon disease
• Rare disease biotech
• Oligonucleotide therapeutics

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pre-revenue clinical-stage biotech: Alltrna is a pre-commercial, clinical-stage biotechnology company. As of early 2026 the company has not generated product revenue; it underwent a third round of layoffs (35% of workforce, 19 employees) and the CEO departed amid restructuring. Revenue is currently entirely sourced from equity financing (e.g., $109M Series B in 2023).

Pricing tiers

Go-to-market motion4 records

Distribution channels3 records

Marketing channels8 records

Core offering

Alltrna develops engineered, chemically modified transfer RNA (tRNA) oligonucleotides designed to read through premature termination codons (PTCs) and restore full-length protein production across thousands of genetic diseases. Its proprietary ML-driven platform screens approximately 10^34 possible tRNA sequences and over 120 chemical modifications per nucleotide to design tRNA medicines that act across multiple diseases sharing the same underlying nonsense mutation. Lead candidate AP003, an Arg-TGA nonsense suppressor encapsulated in a liver-directed lipid nanoparticle (LNP) licensed from Acuitas Therapeutics, is in Phase 1 clinical trials.

Product overview

Alltrna operates a single integrated platform-plus-pipeline architecture: its proprietary ML-driven tRNA Platform sits at the core, generating engineered, chemically modified tRNA oligonucleotides, and its pipeline consists of specific tRNA therapeutic candidates built on that platform. The lead clinical candidate, AP003 (an Arg-TGA-targeting tRNA in a liver-directed LNP licensed from Acuitas Therapeutics), has entered Phase 1 trials for liver Stop Codon Disease. Supporting pipeline programs include the Gln-TAG liver program, an Other Nonsense Mutations liver program, and early-stage Muscle and CNS programs — all intended to be pursued via mutation-defined basket trials. The platform is offered internally only (no external commercial product or API); outputs are tRNA medicines for Stop Codon Disease that address ~30 million patients across thousands of rare and common genetic diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• AP003 Alltrna's first-in-class engineered tRNA oligonucleotide (Arg-TGA nonsense suppressor) encapsulated in a clinically tested, liver-directed lipid nanoparticle (LNP) licensed from Acuitas Therapeutics; designed to read through the arginine-to-TGA premature termination codon and restore full-length protein production in liver Stop Codon Diseases (PKU, organic acidemias, urea cycle disorders, MMA). Currently in Phase 1 clinical evaluation in healthy volunteers in Australia.
• Alltrna tRNA Platform ML-driven programmable tRNA engineering platform combining proprietary machine learning tools, high-throughput screening, computational 3D homology modeling, and chemical synthesis to design, modify, produce, and deliver chemically modified, engineered tRNA oligonucleotides for therapeutic use.
• Arg-TGA Liver Stop Codon Disease Program Pipeline program targeting arginine-to-TGA nonsense mutations in liver diseases including phenylketonuria (PKU), organic acidemias, and urea cycle disorders; anchored by the AP003 clinical candidate. Arg-TGA is the most prevalent nonsense mutation in the liver.
• Gln-TAG Liver Stop Codon Disease Program Pipeline program targeting glutamine-to-TAG nonsense mutations in liver genetic diseases including phenylketonuria, organic acidemias, and urea cycle disorders; leverages the platform's ability to engineer tRNAs for the second most common PTC type.
• Other Nonsense Mutation Liver Program Future platform program intended to engineer tRNA medicines that precisely replace the correct amino acid for additional stop codon types beyond Arg-TGA and Gln-TAG, addressing broader liver Stop Codon Disease patient populations.
• Muscle Stop Codon Disease Program Undisclosed muscle-directed tRNA therapeutic program expanding the platform's reach beyond the liver, targeting Stop Codon Diseases affecting muscle tissue (potentially including Duchenne muscular dystrophy and cystic fibrosis).
• CNS Stop Codon Disease Program Early-stage program exploring tRNA therapeutic delivery to the central nervous system for Stop Codon Diseases of the brain, leveraging the platform's optionality for additional vectors beyond liver-directed LNPs.

Quantifiable outcome

• Restored methylmalonyl-CoA mutase (MMUT) protein to ~25% of wild-type levels in MMA Stop Codon Disease mouse model (well above 1-2% clinically meaningful threshold); remained >1-2% wild type 14 days post-dose.
• +3 more outcomes

Named customers1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Four partnerships are on record, tiered strategic / core technology, patient advocacy partner and regulatory/clinical execution.

• Acuitas Therapeuticsstrategic / core technologyOEM/ Whitelabel/ Licensing PartnerAlltrna licenses Acuitas Therapeutics' clinically tested, liver-directed lipid nanoparticle (LNP) technology for encapsulation of its engineered tRNA oligonucleotides — including AP003, its first clinical-stage tRNA therapeutic. This licensed LNP delivery system underpins Alltrna's lead liver-directed Stop Codon Disease programs (Arg-TGA, Gln-TAG) and is the basis for its initial liver tissue targeting.
• National Organization for Rare Disorders (NORD)patient advocacy partnerGTM or Marketing PartnerNORD is linked from Alltrna's Stop Codon Disease page as a resource offering the latest information about research, advocacy, and care for rare diseases, as well as financial assistance for patients and resources to connect with the rare disease community. NORD also provides a video on genetic testing for patients seeking to understand their mutation status.
• National PKU Alliance (NPKUA)patient advocacy partnerGTM or Marketing PartnerThe National PKU Alliance (NPKUA) is linked from Alltrna's Stop Codon Disease page as a national non-profit organization advocating for the PKU community, working to expand PKU research and accelerate the timeline for a cure — aligning with Alltrna's AP003 PKU program.
• Human Research Ethics Committee (HREC) and Australia's Therapeutic Goods Administration (TGA)regulatory/clinical executionOthersAlltrna's AP003 Phase 1 healthy-volunteer trial was approved under Australia's Therapeutic Goods Administration (TGA) Clinical Trial Notification (CTN) scheme, following review by the Human Research Ethics Committee (HREC). This regulatory pathway enabled Alltrna to initiate its first-in-human tRNA therapeutic trial in Australia.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Alnylam Pharmaceuticals: Alnylam pioneered RNAi-based therapeutics and has a portfolio of approved siRNA medicines for rare genetic diseases. It is a broad incumbent in the oligonucleotide/RNA therapeutics space with overlapping rare-disease commercial and development infrastructure.
• Ionis Pharmaceuticals: Ionis is the leading antisense oligonucleotide (ASO) company, with multiple approved RNA-targeted drugs and a deep rare-disease pipeline. Alltrna's founding COO Lynne Parshall sits on its board, and the platform addresses a similar genetic-disease opportunity from a complementary RNA modality.
• Moderna: Moderna is the leading mRNA therapeutics and vaccines company with significant oligonucleotide chemistry, manufacturing, and LNP delivery expertise. Alltrna's VP of Discovery Platform, Caroline Köhrer, was previously Director of RNA Science at Moderna, providing direct technology overlap.
• BioNTech: BioNTech is a leading mRNA therapeutics company with a growing pipeline in oncology and infectious disease and active expansion into RNA-based genetic medicines. It represents a broad incumbent with the capability to enter the tRNA therapeutics space.

Direct peers

• ReCode Therapeutics: ReCode is developing RNA-based medicines with lipid nanoparticle delivery for genetic diseases including primary ciliary dyskinesia and cystic fibrosis. Its LNP-delivered mRNA and tRNA-style correction programs overlap with Alltrna's mutation-defined, LNP-delivered tRNA approach.
• hC Bioscience: hC Bioscience is a Flagship Pioneering-founded biotech developing programmable tRNA-based therapies for diseases caused by nonsense mutations. It overlaps with Alltrna's core modality and Stop Codon Disease thesis and shares Flagship Pioneering as a common institutional backer.
• Tevard Biosciences: Tevard is developing engineered suppressor tRNAs and other RNA-based therapies to treat genetic diseases caused by nonsense mutations, including Dravet syndrome and Duchenne muscular dystrophy. It is the closest direct competitor to Alltrna in the engineered tRNA therapeutics space, pursuing a similar mutation-defined, gene-agnostic therapeutic thesis.
• Entrada Therapeutics: Entrada develops intracellular oligonucleotide therapeutics for genetic diseases, including Duchenne muscular dystrophy. It is a direct peer in the genetic-medicine oligonucleotide space targeting nonsense and other mutations, and shares former Alltrna CMO Nerissa Kreher, who was previously CMO at Entrada.

Emerging players

• Shape Therapeutics: Shape is an emerging RNA editing and genetic medicines company developing RNAfix™ and other RNA-targeting platforms for genetic diseases. It is an emerging peer with overlapping RNA-based approaches to correcting disease-causing mutations.
• ProQR Therapeutics: ProQR is developing Axiomer® RNA editing oligonucleotide technology and other RNA-targeted therapies for rare genetic diseases including cystic fibrosis and other nonsense-mutation-driven indications. It overlaps with Alltrna's rare genetic disease focus and nonsense-mutation targeting thesis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/alltrna
• LinkedInlinkedin.com/company/alltrna

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alltrna